Exact Sciences announced performance data for its blood-based colorectal cancer (CRC) screening test at the European Society of Medical Oncology (ESMO) Congress, the company announced recently.

According to a release, data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity for negative samples confirmed by colonoscopy.

“The Exact Sciences team is constantly innovating to help close the screening gap,” Exact Sciences chairman and CEO Kevin Conroy said in a statement. “We took a unique scientific approach to developing this test by combining a novel panel of markers. This led to data that improve upon what we previously thought was possible with a blood-based colorectal cancer screening test.”

The study consisted of more than 3,000 blood samples and included more than 90 advanced precancerous lesions.